Laboratory Medicine ›› 2026, Vol. 41 ›› Issue (10): 980-985.DOI: 10.3969/j.issn.1673-8640.2026.10.008
Previous Articles Next Articles
YE Chenggui1, YAN Zhaolan2, WEI Guoyue3(
)
Received:2025-06-17
Revised:2026-03-04
Online:2026-10-30
Published:2026-10-20
CLC Number:
YE Chenggui, YAN Zhaolan, WEI Guoyue. Diagnostic value of procalcitonin combined with intestinal fatty acid-binding protein in the diagnosis of intestinal perforation associated with intestinal tuberculosis[J]. Laboratory Medicine, 2026, 41(10): 980-985.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2026.10.008
| 组别 | 例数 | 年龄/岁 | 性别 | BMI/ (kg·m-2) | 发热/ [例(%)] | 腹痛/ [例(%)] | 吸烟史/ [例(%)] | |
|---|---|---|---|---|---|---|---|---|
| 男[例(%)] | 女[例(%)] | |||||||
| 穿孔组 | 43 | 58.32±5.51 | 25(58.14) | 18(41.86) | 20.81±3.12 | 38(88.37) | 14.22±4.51 | 22(51.16) |
| 未穿孔组 | 80 | 56.73±5.82 | 42(52.50) | 38(47.50) | 22.35±2.90 | 45(56.25) | 9.14±3.34 | 35(43.75) |
| 统计值 | 1.472 | 0.359 | 2.735 | 13.150 | 7.094 | 0.618 | ||
| P值 | 0.144 | 0.549 | 0.007 | <0.001 | <0.001 | 0.432 | ||
| 组别 | 饮酒史/ [例(%)] | 高血压史/ [例(%)] | 糖尿病史/ [例(%)] | WBC计数/ (×109L-1) | CRP/ (mg·L-1) | IL-6/ (pg·mL-1) | ||
| 穿孔组 | 15(34.88) | 18(41.86) | 12(27.91) | 14.22±4.51 | 15.34±3.97 | 29.05±6.24 | ||
| 未穿孔组 | 32(40.00) | 30(37.50) | 20(25.00) | 9.14±3.34 | 13.97±3.86 | 26.82±6.15 | ||
| 统计值 | 0.310 | 0.224 | 3.025 | 7.094 | 1.858 | 1.908 | ||
| P值 | 0.578 | 0.636 | 0.082 | <0.001 | 0.066 | 0.059 | ||
| 组别 | 例数 | 年龄/岁 | 性别 | BMI/ (kg·m-2) | 发热/ [例(%)] | 腹痛/ [例(%)] | 吸烟史/ [例(%)] | |
|---|---|---|---|---|---|---|---|---|
| 男[例(%)] | 女[例(%)] | |||||||
| 穿孔组 | 43 | 58.32±5.51 | 25(58.14) | 18(41.86) | 20.81±3.12 | 38(88.37) | 14.22±4.51 | 22(51.16) |
| 未穿孔组 | 80 | 56.73±5.82 | 42(52.50) | 38(47.50) | 22.35±2.90 | 45(56.25) | 9.14±3.34 | 35(43.75) |
| 统计值 | 1.472 | 0.359 | 2.735 | 13.150 | 7.094 | 0.618 | ||
| P值 | 0.144 | 0.549 | 0.007 | <0.001 | <0.001 | 0.432 | ||
| 组别 | 饮酒史/ [例(%)] | 高血压史/ [例(%)] | 糖尿病史/ [例(%)] | WBC计数/ (×109L-1) | CRP/ (mg·L-1) | IL-6/ (pg·mL-1) | ||
| 穿孔组 | 15(34.88) | 18(41.86) | 12(27.91) | 14.22±4.51 | 15.34±3.97 | 29.05±6.24 | ||
| 未穿孔组 | 32(40.00) | 30(37.50) | 20(25.00) | 9.14±3.34 | 13.97±3.86 | 26.82±6.15 | ||
| 统计值 | 0.310 | 0.224 | 3.025 | 7.094 | 1.858 | 1.908 | ||
| P值 | 0.578 | 0.636 | 0.082 | <0.001 | 0.066 | 0.059 | ||
| 指标 | 例数 | PCT/(ng·mL-1) | I-FABP/ (ng·mL-1) |
|---|---|---|---|
| 正常对照组 | 100 | 0.13±0.04 | 4.26±1.29 |
| 未穿孔组 | 80 | 0.48±0.23* | 12.61±6.33* |
| 穿孔组 | 43 | 2.86±1.72*# | 38.05±13.72*# |
| F值 | 201.440 | 970.267 | |
| P值 | <0.001 | <0.001 |
| 指标 | 例数 | PCT/(ng·mL-1) | I-FABP/ (ng·mL-1) |
|---|---|---|---|
| 正常对照组 | 100 | 0.13±0.04 | 4.26±1.29 |
| 未穿孔组 | 80 | 0.48±0.23* | 12.61±6.33* |
| 穿孔组 | 43 | 2.86±1.72*# | 38.05±13.72*# |
| F值 | 201.440 | 970.267 | |
| P值 | <0.001 | <0.001 |
| 项目 | β值 | 标准误 | Wald值 | P值 | OR①值(95%CI②) |
|---|---|---|---|---|---|
| BMI | -0.125 | 0.078 | 2.563 | 0.109 | 0.883(0.762~1.022) |
| 发热 | 1.234 | 0.456 | 7.321 | 0.007 | 3.435(1.452~8.147) |
| 腹痛 | 0.852 | 0.376 | 5.381 | 0.020 | 2.392(1.145~4.998) |
| WBC计数 | 0.098 | 0.034 | 8.294 | 0.004 | 1.103(1.031~1.180) |
| PCT | 0.215 | 0.089 | 5.842 | 0.016 | 1.240(1.042~1.475) |
| I-FABP | 0.321 | 0.123 | 6.945 | 0.009 | 1.379(1.087~1.752) |
| 项目 | β值 | 标准误 | Wald值 | P值 | OR①值(95%CI②) |
|---|---|---|---|---|---|
| BMI | -0.125 | 0.078 | 2.563 | 0.109 | 0.883(0.762~1.022) |
| 发热 | 1.234 | 0.456 | 7.321 | 0.007 | 3.435(1.452~8.147) |
| 腹痛 | 0.852 | 0.376 | 5.381 | 0.020 | 2.392(1.145~4.998) |
| WBC计数 | 0.098 | 0.034 | 8.294 | 0.004 | 1.103(1.031~1.180) |
| PCT | 0.215 | 0.089 | 5.842 | 0.016 | 1.240(1.042~1.475) |
| I-FABP | 0.321 | 0.123 | 6.945 | 0.009 | 1.379(1.087~1.752) |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| PCT | 0.875(0.815~0.935) | 1.02 ng/mL | 81.8 | 83.3 | 0.651 |
| I-FABP | 0.776(0.694~0.858) | 16.49 pg/mL | 77.3 | 77.3 | 0.546 |
| 联合检测 | 0.933(0.885~0.980) | 0.42 | 81.8 | 97.0 | 0.788 |
| 项目 | AUC(95%CI) | 最佳临界值 | 敏感性/% | 特异性/% | Youden指数 |
|---|---|---|---|---|---|
| PCT | 0.875(0.815~0.935) | 1.02 ng/mL | 81.8 | 83.3 | 0.651 |
| I-FABP | 0.776(0.694~0.858) | 16.49 pg/mL | 77.3 | 77.3 | 0.546 |
| 联合检测 | 0.933(0.885~0.980) | 0.42 | 81.8 | 97.0 | 0.788 |
| [1] | Vargas Rodríguez A E, Godinez Vidal A R, Alcántara Gordillo R, et al. A case report and literature review of intestinal perforation due to tuberculosis[J]. Cureus, 2023, 15(8):e43241. |
| [2] |
Huang P, Luo N, Shi X, et al. Risk factor analysis and nomogram prediction model construction for NEC complicated by intestinal perforation[J]. BMC Pediatr, 2024, 24(1):143.
DOI PMID |
| [3] | 王双. 结肠穿孔所致腹腔感染患者腹水病原菌分布及死亡因素分析[J]. 中国肛肠病杂志, 2025, 45(1):29-32. |
| [4] | 李枫林, 孙金华, 孙媛媛, 等. 微生态制剂联合膳食纤维对慢性阻塞性肺疾病及肠道菌群和炎症因子的影响[J]. 实用临床医药杂志, 2025, 29(2):90-95. |
| [5] | 中国疾病预防控制中心结核病预防控制中心. 中国结核病防治工作技术指南[M]. 北京: 人民卫生出版社, 2021. |
| [6] | 荆申奥, 马蓉蓉, 张瑞, 等. 基于常见不良事件评价标准的药物不良反应严重程度再评估[J]. 药物不良反应杂志, 2025, 27(12):745-751. |
| [7] | 陈建勇, 陈杰, 王爱瑶, 等. 肠结核实验室诊断技术的研究进展[J]. 江西医药, 2024, 59(8):707-709. |
| [8] |
Xu K, Tan J, Lin D, et al. Gut microbes of the cecum versus the colon drive more severe lethality and multi-organ damage[J]. Int Immunopharmacol, 2025, 147:114029.
DOI URL |
| [9] |
Ahmed S, Hafez W, El Chayeb J, et al. Intestinal tuberculosis and inflammatory bowel disease; the usual challenging differential diagnoses:a case report[J]. Radiol Case Rep, 2023, 18(10):3680-3685.
DOI URL |
| [10] |
He R R, Yue G L, Dong M L, et al. Sepsis biomarkers:advancements and clinical applications-a narrative review[J]. Int J Mol Sci, 2024, 25(16):9010.
DOI URL |
| [11] |
Varkila M R J, Verboom D M, Derde L P G, et al. Gut barrier dysfunction and the risk of ICU-acquired bacteremia- a case-control study[J]. Ann Intensive Care, 2024, 14(1):42.
DOI PMID |
| [12] |
Liu S, Liu Y, Lai S, et al. Values of serum intestinal fatty acid-binding protein,fecal calprotectin,and fecal human β-defensin 2 for predicting necrotizing enterocolitis[J]. BMC Pediatr, 2024, 24(1):183.
DOI |
| [13] |
Randeni N, Bordiga M, Xu B. A comprehensive review of the triangular relationship among diet-gut microbiota-inflammation[J]. Int J Mol Sci, 2024, 25(17):9366.
DOI URL |
| [14] |
Qiu P, Wu C, Zhang X, et al. Towards building multilingual language model for medicine[J]. Nat Commun, 2024, 15(1):8384.
DOI PMID |
| [15] |
Chen L, Chen X. The role of different systemic inflammatory indexes derived from complete blood count in differentiating acute from chronic calculus cholecystitis and predicting its severity[J]. J Inflamm Res, 2024, 17:2051-2062.
DOI PMID |
| [16] |
Xiangyuan C, Xiaoling Z, Guangchao S, et al. Juvenile dermatomyositis complications:navigating gastrointestinal perforations and treatment challenges,a case report[J]. Front Pediatr, 2024, 12:1419355.
DOI URL |
| [17] |
Un Nisa Z, Ambreen A, Mustafa T. Persistently high plasma procalcitonin levels despite successful treatment of tuberculous pleuritis and tuberculous lymphadenitis patients[J]. Sci Rep, 2024, 14(1):22590.
DOI PMID |
| [18] |
Gaffar S, Aathirah A S. Fatty-acid-binding proteins:from lipid transporters to disease biomarkers[J]. Biomolecules, 2023, 13(12):1753.
DOI URL |
| [19] |
Chen J, Yan Z, Lin Z, et al. I-FABP protein/mRNA and IL-6 as biomarkers of intestinal barrier dysfunction in neonates with necrotizing enterocolitis and SPF BALB/cmouse models[J]. J Int Med Res, 2024, 52(6):3000605241254788.
DOI URL |
| [20] | 吕颜智, 周业江. 血清降钙素原对急性消化道穿孔部位的预测价值[J]. 中华急诊医学杂志, 2021, 30(11):1353-1357. |
| [21] | Wu J, Shu P, He H, et al. Predictors of mortality in patients with acute small-bowel perforation transferred to ICU after emergency surgery:a single-centre retrospective cohort study[J]. Gastroenterol Rep(Oxf), 2021,10:goab054. |
| [1] | HU Mingxi, GONG Qian, LI Mu, PENG Rong. Role of PCT,DD,Lac and Alb combined with clinical scores in progression assessment of sepsis [J]. Laboratory Medicine, 2026, 41(1): 63-68. |
| [2] | YIN Liangping, YUAN Yongming, QU Bin, LI Wenna, ZHANG Shu. Role of neutrophil CD64 absolute value determined by cell solid-phase chip method in bacterial infectious disease diagnosis [J]. Laboratory Medicine, 2025, 40(6): 571-575. |
| [3] | ZHANG Haoyang, LU Lin, ZONG Ming, HE Long, DING Yuanyuan, FAN Lieying. Diagnostic and predictive value of white blood cell population data in patients with sepsis [J]. Laboratory Medicine, 2025, 40(3): 271-277. |
| [4] | DAI Yao, LI Jiahui, XU Xiuhong. Prognosis evaluation model of children with Mycoplasma pneumoniae pneumonia based on MP DNA and peripheral blood inflammation indicators [J]. Laboratory Medicine, 2024, 39(6): 568-572. |
| [5] | JIANG Jingjing, GU Ping, WANG Chengyun, ZHANG Fan, SHEN Huiying, PAN Qiuhui, WANG Jing. Changes and clinical significance of procalcitonin and coagulation function indicators in children with sepsis [J]. Laboratory Medicine, 2024, 39(6): 573-577. |
| [6] | SUN Kangde, YU Zhongmin, YAN Yuzhong. Roles on early diagnosis and prognosis of different infection indicators for bloodstream infection [J]. Laboratory Medicine, 2024, 39(3): 222-226. |
| [7] | LI Li, SUN Haiyan, LI Yuanrui, DOU Min, TANG Wen, JIANG Limin, SHEN Lisong. Changes and clinical roles of perioperative NT-proBNP and PCT in children with congenital heart disease [J]. Laboratory Medicine, 2023, 38(6): 524-531. |
| [8] | ZHAI Shana, SUN Qinghai, YU Yongwu, YE Fang, LIU Maodong. Influence of vancomycin combined with meropenem on serum TNF-α,PCT,IL-6 and peritoneal fluid WBC count in PDRP patients [J]. Laboratory Medicine, 2022, 37(4): 360-364. |
| [9] | GU Feng, WU Yanfen, ZHAO Xinhui, HOU Zhaoyuan, WANG Zhihong, QI Hualin. Relationship between procalcitonin level and all-cause death in maintenance hemodialysis patients [J]. Laboratory Medicine, 2022, 37(2): 134-140. |
| [10] | HE Xuelian, HE Ziyi, LIU Yueyang, YU Yanzhi, ZHANG Siying. Role of line chart model based on peripheral blood-derived inflammation markers in early diagnosis of neonatal septicemia [J]. Laboratory Medicine, 2022, 37(10): 921-927. |
| [11] | ZHU Chuanxin, ZHOU Yuping, HE Yan, ZHOU Qin. Diagnostic role of NLR,CRP,PCT,DD and NT-proBNP in severe corona virus disease 2019 [J]. Laboratory Medicine, 2021, 36(2): 190-193. |
| [12] | PAN Xilong, XU Zhiyuan, XIE Feng, LI Dan. Role of procalcitonin in the diagnosis of different sepsis [J]. Laboratory Medicine, 2021, 36(12): 1215-1218. |
| [13] | ZHU Chuanxin, ZHOU Yuping, ZHOU Qin, ZHOU Guifeng. Early diagnosis value of NLR,PCT and CRP combined determination for COVID-19 [J]. Laboratory Medicine, 2021, 36(1): 53-56. |
| [14] | ZHAO Minghai, LI Xin, WEI Dong, LUO Min, ZHANG Yajie, YANG Yiqi, ZHENG Lei. Influence of dry heat inactive treatment for the determination of inflammatory indicators related with corona virus disease 2019 [J]. Laboratory Medicine, 2020, 35(9): 924-927. |
| [15] | LU Xiufen, HE Zhijun, LIU Qiting, FENG Zhongxin, MA Sheng. Serum procalcitonin and urine endotoxin determinations for guiding CAUTI antimicrobial therapy [J]. Laboratory Medicine, 2020, 35(7): 686-690. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||